These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30460518)

  • 21. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apixaban Level and Its Influence on Immunosuppression and Graft Outcome in Kidney Transplant Recipients With Atrial Fibrillation.
    Green H; Rahamimov R; Spectre G; Rozen-Zvi B; Fuchs S; Avni S; Nissan R
    Ther Drug Monit; 2021 Oct; 43(5):637-644. PubMed ID: 33337589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation.
    Mavri A; Vene N; Božič-Mijovski M; Miklič M; Söderblom L; Pohanka A; Malmström RE; Antovic J
    Sci Rep; 2021 Jul; 11(1):13908. PubMed ID: 34230559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of age on the relationship between apixaban concentration and anti-factor Xa activity in older patients with non-valvular atrial fibrillation.
    Kalaria SN; Zhu H; Liu Q; Florian J; Wang Y; Schwartz J
    Int J Cardiol; 2021 May; 331():109-113. PubMed ID: 33529664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
    Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
    Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
    Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
    Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.
    Aakerøy R; Loennechen JP; Dyrkorn R; Lydersen S; Helland A; Spigset O
    PLoS One; 2024; 19(7):e0308022. PubMed ID: 39083480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
    Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
    JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
    Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
    Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
    Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
    Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.